CL2017001190A1 - Nuevos agonistas de npr-b. (divisional de solicitud 715-2012) - Google Patents

Nuevos agonistas de npr-b. (divisional de solicitud 715-2012)

Info

Publication number
CL2017001190A1
CL2017001190A1 CL2017001190A CL2017001190A CL2017001190A1 CL 2017001190 A1 CL2017001190 A1 CL 2017001190A1 CL 2017001190 A CL2017001190 A CL 2017001190A CL 2017001190 A CL2017001190 A CL 2017001190A CL 2017001190 A1 CL2017001190 A1 CL 2017001190A1
Authority
CL
Chile
Prior art keywords
npr
divisional application
new agonists
new
agonists
Prior art date
Application number
CL2017001190A
Other languages
English (en)
Inventor
Mark R Hellberg
Frank Osterkamp
Heiko Hawlisch
Gerd Hummel
Ulf Reimer
Ulrich Reineke
Uwe Richter
Bernadett Simon
Edgar Specker
Markus Woischnik
Tobias Knaute
Original Assignee
Shire Orphan Therapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43781057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001190(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Orphan Therapies Gmbh filed Critical Shire Orphan Therapies Gmbh
Publication of CL2017001190A1 publication Critical patent/CL2017001190A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>SE DIVULGAN NUEVOS COMPUESTOS QUE TIENEN ACTIVIDAD AGONISTA DE NPR-B. LOS COMPUESTOS PREFERIDOS SON PÉPTIDOS LINEALES QUE CONTIENEN 8-13 RESIDUOS DE L- O D. AMINO ÁCIDOS CONVENCIONALES O NO CONVENCIONALES CONECTADOS UNO A OTRO MEDIANTE ENLACES PEPTIDÍCOS.</p>
CL2017001190A 2009-09-25 2017-05-11 Nuevos agonistas de npr-b. (divisional de solicitud 715-2012) CL2017001190A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25

Publications (1)

Publication Number Publication Date
CL2017001190A1 true CL2017001190A1 (es) 2017-12-01

Family

ID=43781057

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2012000715A CL2012000715A1 (es) 2009-09-25 2012-03-22 Compuesto agonista del receptor de peptido natriuretico b (npr-b), que comprende peptidos lineales que contienen 9 residuos aminoacidicos; y su uso para preparar un medicamento para disminuir la presion intraocular.
CL2017001190A CL2017001190A1 (es) 2009-09-25 2017-05-11 Nuevos agonistas de npr-b. (divisional de solicitud 715-2012)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2012000715A CL2012000715A1 (es) 2009-09-25 2012-03-22 Compuesto agonista del receptor de peptido natriuretico b (npr-b), que comprende peptidos lineales que contienen 9 residuos aminoacidicos; y su uso para preparar un medicamento para disminuir la presion intraocular.

Country Status (17)

Country Link
US (5) US8546523B2 (es)
EP (1) EP2480247B1 (es)
JP (3) JP5893561B2 (es)
KR (3) KR101854820B1 (es)
CN (2) CN105732767A (es)
AR (1) AR078445A1 (es)
AU (1) AU2010298256B2 (es)
BR (1) BR112012006579A2 (es)
CA (1) CA2773949C (es)
CL (2) CL2012000715A1 (es)
MX (3) MX370645B (es)
PH (1) PH12012500562A1 (es)
RU (3) RU2636738C2 (es)
TW (2) TWI625126B (es)
UY (1) UY32902A (es)
WO (1) WO2011038061A2 (es)
ZA (3) ZA201201630B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1865976T3 (pl) 2005-04-07 2012-11-30 Cardiorentis Ag Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
US20090311258A1 (en) * 2006-08-02 2009-12-17 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
WO2011038061A2 (en) * 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
HK1202433A1 (en) * 2011-12-16 2015-10-02 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
AP2015008624A0 (en) * 2013-01-25 2015-07-31 Cardiorentis Ltd Methods of treating cardiovascular indications
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
US20180215788A1 (en) 2017-02-01 2018-08-02 Shire Human Genetic Therapies, Inc. Compounds and Compositions for the Treatment of Ophthalmic Disorders
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
TWI828800B (zh) * 2018-11-16 2024-01-11 美商阿克思生物科學有限公司 Arg1及/或arg2之抑制劑
CN115803338A (zh) * 2020-06-12 2023-03-14 药明公司 C型利尿钠肽及其治疗急性肺损伤的方法
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) * 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
WO1989005654A1 (en) * 1987-12-24 1989-06-29 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
JP2848411B2 (ja) 1988-08-18 1999-01-20 サイオス インコーポレイテッド 心房性ナトリウム利尿ペプチドクリアランス阻害剤
WO2000018422A1 (fr) 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2006005140A2 (en) * 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20090035287A1 (en) * 2005-09-26 2009-02-05 Zurit Levine Atrial natriuretic peptide (anp) splice variants and methods of using same
WO2007047504A2 (en) 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
CA2647143A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
EP2004633A4 (en) * 2006-03-30 2009-08-26 Palatin Technologies Inc LINEAR NATRIURETIC PEPTIDE CONSTRUCTS
EP2217620A2 (en) * 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
US8551938B2 (en) 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
WO2011038061A2 (en) * 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.

Also Published As

Publication number Publication date
CN102548574A (zh) 2012-07-04
US20180334477A1 (en) 2018-11-22
EP2480247B1 (en) 2020-02-12
PH12012500562A1 (en) 2012-10-22
CA2773949A1 (en) 2011-03-31
TW201630619A (zh) 2016-09-01
WO2011038061A3 (en) 2011-07-28
US9982016B2 (en) 2018-05-29
TW201110974A (en) 2011-04-01
JP5893561B2 (ja) 2016-03-23
WO2011038061A2 (en) 2011-03-31
US9169293B2 (en) 2015-10-27
EP2480247A2 (en) 2012-08-01
CN102548574B (zh) 2016-03-23
RU2017139870A (ru) 2019-05-16
BR112012006579A2 (pt) 2016-11-22
UY32902A (es) 2011-02-28
MX2012003398A (es) 2012-04-10
US20170313743A1 (en) 2017-11-02
RU2636738C2 (ru) 2017-11-28
KR20180049198A (ko) 2018-05-10
KR101854820B1 (ko) 2018-05-04
ZA201702958B (en) 2018-08-29
CN105732767A (zh) 2016-07-06
JP2017137362A (ja) 2017-08-10
RU2015124607A (ru) 2015-12-10
AU2010298256A1 (en) 2012-04-12
MX370645B (es) 2019-12-19
AU2010298256B2 (en) 2015-08-13
MX354005B (es) 2018-02-08
KR20120091110A (ko) 2012-08-17
US10196423B2 (en) 2019-02-05
JP6211032B2 (ja) 2017-10-11
ZA201401625B (en) 2018-08-25
US20110077381A1 (en) 2011-03-31
CL2012000715A1 (es) 2012-11-30
US20160194357A1 (en) 2016-07-07
US8546523B2 (en) 2013-10-01
RU2017139870A3 (es) 2019-05-16
RU2012116531A (ru) 2013-10-27
TWI577384B (zh) 2017-04-11
ZA201201630B (en) 2014-05-28
RU2557290C2 (ru) 2015-07-20
EP2480247A4 (en) 2013-09-04
JP2015131856A (ja) 2015-07-23
JP2013505937A (ja) 2013-02-21
US20130345394A1 (en) 2013-12-26
KR20170094564A (ko) 2017-08-18
KR101768661B1 (ko) 2017-08-16
AR078445A1 (es) 2011-11-09
TWI625126B (zh) 2018-06-01
CA2773949C (en) 2020-11-03
US9745344B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
CL2017001190A1 (es) Nuevos agonistas de npr-b. (divisional de solicitud 715-2012)
CL2012002884A1 (es) Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido.
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
EP2185170A4 (en) COMPOSITION FOR PEPTIDE ANALOGUE WITH LONG-TERM EFFECT
PA8802301A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonistas del glp-1
ECSP10010471A (es) Agonistas nicotínicos alfa 7 y antipsicóticos
UA106586C2 (uk) Анти-cd79b антитіла, і імунокон&#39;югати та способи їх застосування
MX2010004571A (es) Composiciones y metodos que comprenden peptidos y proteasas de aminoacidos basicos.
CL2011002036A1 (es) Analogo peptidico doble agonista de los receptores de glp-1 y de glucagon.
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
EP2411038A4 (en) PARATHYOIDHORMONEPEPTIDES AND PARATHYROIDHORMONE-RELATED PROTEINPEPTIDES AND METHOD OF USE THEREOF
BR112012019042A2 (pt) &#34;inibidores de serina protease tipo tripsina, e sua preparação e uso&#34;.
UA118167C2 (uk) Пептид та його застосування
UA109949C2 (uk) Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання
BR112012013469A2 (pt) composições orais contendo extratos de garcinia mangostana l. e métodos relacionados
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
EA201390182A1 (ru) Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
CY1117328T1 (el) Διαδικασια για την παρασκευη πολυσιαλικου οξεος υψηλης καθαρiοτητας
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
MX2011007736A (es) Compuestos de hormona del crecimiento estables.
SV2010003748A (es) Preg-4-en-21, 17-carbolactonas sustituidas en el anillo c, asi como preparados farmaceuticos que las contienen
ECSP109947A (es) Péptido (dn81) optimizado inhibitorio de la entrada del virus del dengue
ATE451112T1 (de) Oligopeptide enthaltende dermatologische zusammensetzungen zur steigerung der hautempfindlichkeit
UA103290C2 (ru) Фармацевтическая композиция ибупрофена для инъекции